Yi Chenggang, Xia Wei, Zheng Yan, Zhang Lingxi, Shu Maoguo, Liang Jie, Han Yan, Guo Shuzhong
Department of Plastic Surgery, Xijing Hospital Fourth Military Medical University, Xi'an, Shaanxi Province, China.
J Surg Res. 2006 Sep;135(1):100-6. doi: 10.1016/j.jss.2006.01.014. Epub 2006 Mar 29.
Neovascularization occurs through two mechanisms: angiogenesis and vasculogenesis. Therefore, there are two strategies to promote neovascularization: therapeutic angiogenesis and therapeutic vasculogenesis (endothelial progenitor cells therapy).
In this study, we examined whether or not endothelial progenitor cells combined with vascular endothelial growth factor (VEGF) gene therapy is useful for ischemia surgical flaps in vivo. At the same time, we quantitatively compared the neovascularization ability of transplanted endothelial progenitor cells (EPCs) transducted with VEGF165 gene and EPCs alone. EPCs were isolated from cord blood of healthy human volunteers, cultured in vitro for 7 days and identified by immunofluorescence. After transduced with VEGF165 gene in vitro, proliferative activity of EPCs was assessed using MTT assay. CM-DiI was used to trace EPCs in vivo 4 days after injection of 5 x 10(5) VEGF-transduced EPCs(VEGF-transduced EPCs group, n = 10), 5 x 10(5) EPCs (non-transduced EPCs group, n = 10) in 500 microL EBM-2 media, or 500 microL EBM-2 media (EBM-2 media group, n = 10) local, a cranially based flap was elevated on the back of nude mice. The percent flap survival, neovasculariztion and blood flow recovery of flaps was detected.
EPCs expressed cell markers CD34, KDR, and CD133. A statistically significant increase in percent flap survival was observed in mice of VEGF-transduced EPCs group as compared with that of non-transduced EPCs group: 67.99 +/- 6.64% versus 59.43 +/- 4.69% (P < 0.01), and 41.24 +/- 2.44% in EBM-2 media group (P < 0.01). The capillary density and blood flow recovery of flaps in VEGF-transduced EPCs group were both improved. CM-DiI-labeled VEGF-transduced EPCs were observed in vivo and the numbers of cells increased.
EPCs from human cord blood can increased neovascularization of ischemic flaps and augmented the survival areas, and VEGF-transduced EPCs have more powerful ability of promoting neovascularization in animal model of ischemic flaps.
新生血管形成通过两种机制发生:血管生成和血管发生。因此,有两种促进新生血管形成的策略:治疗性血管生成和治疗性血管发生(内皮祖细胞疗法)。
在本研究中,我们检测了内皮祖细胞联合血管内皮生长因子(VEGF)基因治疗对体内缺血手术皮瓣是否有用。同时,我们定量比较了转导VEGF165基因的移植内皮祖细胞(EPCs)和单独的EPCs的新生血管形成能力。从健康人类志愿者的脐带血中分离EPCs,体外培养7天并通过免疫荧光鉴定。体外转导VEGF165基因后,使用MTT法评估EPCs的增殖活性。在500微升EBM-2培养基中注射5×10⁵个转导VEGF的EPCs(转导VEGF的EPCs组,n = 10)、5×10⁵个EPCs(未转导的EPCs组,n = 10)或500微升EBM-2培养基(EBM-2培养基组,n = 10)4天后,用CM-DiI在体内追踪EPCs,在裸鼠背部掀起一个蒂在头侧的皮瓣。检测皮瓣的存活百分比、新生血管形成和血流恢复情况。
EPCs表达细胞标志物CD34、KDR和CD133。与未转导的EPCs组相比,转导VEGF的EPCs组小鼠皮瓣存活百分比有统计学显著增加:67.99±6.64%对59.43±4.69%(P < 0.01),EBM-2培养基组为41.24±2.44%(P < 0.01)。转导VEGF的EPCs组皮瓣的毛细血管密度和血流恢复均得到改善。在体内观察到CM-DiI标记的转导VEGF的EPCs,且细胞数量增加。
人脐带血来源的EPCs可增加缺血皮瓣的新生血管形成并扩大存活面积,在缺血皮瓣动物模型中转导VEGF的EPCs具有更强的促进新生血管形成的能力。